Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission
Significant differences exist in the availability of healthcare worker (HCW) SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Over a 3 week period (April 2020), 1032 asymptomatic HCWs were screened for SARS-CoV-2 in a large UK teaching hospital. Symptomatic staff and symptomatic household contacts were additionally tested. Real-time RT-PCR was used to detect viral RNA from a throat+nose self-swab. 3% of HCWs in the asymptomatic screening group tested positive for SARS-CoV-2. 17/30 (57%) were truly asymptomatic/pauci-symptomatic. 12/30 (40%) had experienced symptoms compatible with coronavirus disease 2019 (COVID-19)>7 days prior to testing, most self-isolating, returning well. Clusters of HCW infection were discovered on two independent wards. Viral genome sequencing showed that the majority of HCWs had the dominant lineage B∙1. Our data demonstrates the utility of comprehensive screening of HCWs with minimal or no symptoms. This approach will be critical for protecting patients and hospital staff..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
eLife - 9(2020) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lucy Rivett [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Biology (General) |
|---|
| doi: |
10.7554/eLife.58728 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ020485956 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ020485956 | ||
| 003 | DE-627 | ||
| 005 | 20230307035815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7554/eLife.58728 |2 doi | |
| 035 | |a (DE-627)DOAJ020485956 | ||
| 035 | |a (DE-599)DOAJcc538b51221c425e9c7cee66c061f849 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QH301-705.5 | |
| 100 | 0 | |a Lucy Rivett |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Significant differences exist in the availability of healthcare worker (HCW) SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Over a 3 week period (April 2020), 1032 asymptomatic HCWs were screened for SARS-CoV-2 in a large UK teaching hospital. Symptomatic staff and symptomatic household contacts were additionally tested. Real-time RT-PCR was used to detect viral RNA from a throat+nose self-swab. 3% of HCWs in the asymptomatic screening group tested positive for SARS-CoV-2. 17/30 (57%) were truly asymptomatic/pauci-symptomatic. 12/30 (40%) had experienced symptoms compatible with coronavirus disease 2019 (COVID-19)>7 days prior to testing, most self-isolating, returning well. Clusters of HCW infection were discovered on two independent wards. Viral genome sequencing showed that the majority of HCWs had the dominant lineage B∙1. Our data demonstrates the utility of comprehensive screening of HCWs with minimal or no symptoms. This approach will be critical for protecting patients and hospital staff. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a virology | |
| 650 | 4 | |a occupational health | |
| 650 | 4 | |a emerging pathogens | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 653 | 0 | |a Biology (General) | |
| 700 | 0 | |a Sushmita Sridhar |e verfasserin |4 aut | |
| 700 | 0 | |a Dominic Sparkes |e verfasserin |4 aut | |
| 700 | 0 | |a Matthew Routledge |e verfasserin |4 aut | |
| 700 | 0 | |a Nick K Jones |e verfasserin |4 aut | |
| 700 | 0 | |a Sally Forrest |e verfasserin |4 aut | |
| 700 | 0 | |a Jamie Young |e verfasserin |4 aut | |
| 700 | 0 | |a Joana Pereira-Dias |e verfasserin |4 aut | |
| 700 | 0 | |a William L Hamilton |e verfasserin |4 aut | |
| 700 | 0 | |a Mark Ferris |e verfasserin |4 aut | |
| 700 | 0 | |a M Estee Torok |e verfasserin |4 aut | |
| 700 | 0 | |a Luke Meredith |e verfasserin |4 aut | |
| 700 | 0 | |a The CITIID-NIHR COVID-19 BioResource Collaboration |e verfasserin |4 aut | |
| 700 | 0 | |a Martin D Curran |e verfasserin |4 aut | |
| 700 | 0 | |a Stewart Fuller |e verfasserin |4 aut | |
| 700 | 0 | |a Afzal Chaudhry |e verfasserin |4 aut | |
| 700 | 0 | |a Ashley Shaw |e verfasserin |4 aut | |
| 700 | 0 | |a Richard J Samworth |e verfasserin |4 aut | |
| 700 | 0 | |a John R Bradley |e verfasserin |4 aut | |
| 700 | 0 | |a Gordon Dougan |e verfasserin |4 aut | |
| 700 | 0 | |a Kenneth GC Smith |e verfasserin |4 aut | |
| 700 | 0 | |a Paul J Lehner |e verfasserin |4 aut | |
| 700 | 0 | |a Nicholas J Matheson |e verfasserin |4 aut | |
| 700 | 0 | |a Giles Wright |e verfasserin |4 aut | |
| 700 | 0 | |a Ian G Goodfellow |e verfasserin |4 aut | |
| 700 | 0 | |a Stephen Baker |e verfasserin |4 aut | |
| 700 | 0 | |a Michael P Weekes |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t eLife |d eLife Sciences Publications Ltd, 2013 |g 9(2020) |w (DE-627)DOAJ000080845 |x 2050084X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |
| 856 | 4 | 0 | |u https://doi.org/10.7554/eLife.58728 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/cc538b51221c425e9c7cee66c061f849 |z kostenfrei |
| 856 | 4 | 0 | |u https://elifesciences.org/articles/58728 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2050-084X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 | ||